Abstract
To control the coronavirus disease 2019 (COVID-19) pandemic and the emergence of different variants of concern (VoCs), novel vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed. In this study, we report the potent immunogenicity and efficacy induced in hamsters by a vaccine candidate based on a modified vaccinia virus Ankara (MVA) vector expressing a human codon optimized full-length SARS-CoV-2 spike (S) protein (MVA-S). Immunization with one or two doses of MVA-S elicited high titers of S- and receptor-binding domain (RBD)-binding IgG antibodies and neutralizing antibodies against parental SARS-CoV-2 and VoC alpha, beta, gamma, delta, and omicron. After SARS-CoV-2 challenge, MVA-S-vaccinated hamsters showed a significantly strong reduction of viral RNA and infectious virus in the lungs compared to the MVA-WT control group. Moreover, a marked reduction in lung histopathology was also observed in MVA-S-vaccinated hamsters. These results favor the use of MVA-S as a potential vaccine candidate for SARS-CoV-2 in clinical trials.
Keywords: COVID-19; MVA vaccine; SARS-CoV-2; efficacy; hamsters; immunogenicity; spike.
【저자키워드】 COVID-19, SARS-CoV-2, Efficacy, immunogenicity, hamsters, Spike., MVA vaccine, 【초록키워드】 coronavirus disease, neutralizing antibody, Coronavirus disease 2019, Vaccine, coronavirus, immunogenicity, pandemic, Neutralizing antibodies, hamsters, variants of concern, lung, clinical trials, severe acute respiratory syndrome Coronavirus, omicron, immunization, Protein, IgG antibody, Viral, Receptor-binding domain, IgG antibodies, Lungs, VOCs, vaccine candidate, Alpha, Beta, Viral RNA, hamster, respiratory, Infectious virus, dose, reduction, acute respiratory syndrome, control group, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, domain, favor, novel vaccines, modified vaccinia virus, Lung histopathology, significantly, expressing, reduction in, elicited, parental, full-length SARS-CoV-2, 【제목키워드】 hamster, concern, candidate, Against,